April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Genetic survey of primary LHON-causing mtDNA mutations as well as OPA1 and OPA3 mutations in 522 Chinese families with suspected hereditary optic neuropathy
Author Affiliations & Notes
  • Yang Li
    Beijing Inst of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Jieqiong Chen
    Beijing Inst of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Xiaohui Zhang
    Beijing Inst of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Ke Xu
    Beijing Inst of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Bing Dong
    Beijing Inst of Ophthalmology, Beijing Tongren Hospital, Beijing, China
  • Footnotes
    Commercial Relationships Yang Li, None; Jieqiong Chen, None; Xiaohui Zhang, None; Ke Xu, None; Bing Dong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6200. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yang Li, Jieqiong Chen, Xiaohui Zhang, Ke Xu, Bing Dong; Genetic survey of primary LHON-causing mtDNA mutations as well as OPA1 and OPA3 mutations in 522 Chinese families with suspected hereditary optic neuropathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6200.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Autosomal dominant optic atrophy (ADOA) and Leber’s hereditary optic neuropathy (LHON) are the commonest forms of hereditary optic atrophy The aim of this study was to report the results of molecular screening of the OPA1, OPA3 gene, and primary LHON-causing mtDNA mutations in a cohort of patients with suspected hereditary optic neuropathy.

Methods: Patients and unaffected individuals from the 522 unrelated families were collected and underwent detailed ophthalmic examinations. Fourteen primary LHON-causing mtDNA mutations were initially screened by PCR-based sequencing methods for all patients except the individuals with a father-to-son transmission family history. All coding exons of the OPA1 and OPA3 gene were then screened for mutations by direct sequencing of PCR-amplified DNA fragments. A large deletion of the OPA1 gene was detected by multiplex ligation probe amplification (MLPA) assay.

Results: 522 unrelated probands from 522 Chinese families were diagnosed with suspected hereditary neuropathy optic neuropathies. Molecular defects were identified in 322 probands (61.8% of the screened probands). Among these, 273 patients (84.9%) had an mtDNA mutation, 47 patients (14.6%) carried an OPA1 mutation, and 2 patients (0.6%) had an OPA3 mutation. Only 43% (118/273) patients of LHON had family history and the affected male-to-female ratio was 7.5:1 for the all probands. The three common primary LHON mutations were identified in 92.7 % (253/273) patients, rare primary mutations were detected in less 8% patients. Of the 47 probands with the OPA1 mutation, 42.5% cases had family history and the affected male-to-female ratio was 1.2:1 for the all probands. The mean onset age (19.25±8.42 years) of the LHON patients was significantly older than the one (8.21±7.52years) of the ADOA patients. There was a significant difference (P<0.01) in visual outcome between the patients with LHON and ADOA, with the mean logMAR visual acuity for patients with LHON mutations (1.3±0.65) being worse compared with those harboring OPA1 mutations (0.76±0.38). Forty mutations of the OPA1 gene were identified and 23 of which were novel. Three large OPA1 duplications were identified by the MLPA analysis.

Conclusions: This study implies that the frequency of ADOA is much lower than that of LHON in Chinese compared with other ethnic groups.

Keywords: 629 optic nerve • 600 mitochondria • 604 mutations  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×